Funding for this research was provided by:
Alzheimer Society (440 (AS-CTF-18-006))
Received: 30 November 2020
Accepted: 2 October 2021
First Online: 10 November 2021
: ADNI received US ethical approval from 58 study locations with all participants providing informed consent (ClinicalTrials.gov identifier: NCT01231971).
: Not applicable. The datasets generated during the current study will be available in the github repository, ExternalRef removed.
: P.M.M. acknowledges consultancy fees from Roche, Adelphi Communications, Celgene and Biogen. He has received honoraria or speakers’ honoraria from Novartis, Biogen and Roche and has received research or educational funds from Biogen, Novartis, GlaxoSmithKline and Nodthera. He is a member of the Scientific Advisory Board to the Board of Ipsen Pharmaceuticals. A.W. and E.A.R are employees of Invicro LLC. All are outside the scope of the article.